Literature DB >> 33738052

Novel Bicyclic Heterocycles as FGFR Inhibitors for Treating Cancer.

Ram W Sabnis1.   

Abstract

Entities:  

Year:  2021        PMID： 33738052      PMCID： PMC7957934          DOI： 10.1021/acsmedchemlett.1c00075

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  5 in total

Review 1.  The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.

Authors:  Robert Roskoski
Journal:  Pharmacol Res       Date:  2019-11-23       Impact factor: 7.658

Review 2.  Recent advance in the development of novel, selective and potent FGFR inhibitors.

Authors:  Feng-Tao Liu; Nian-Guang Li; Yan-Min Zhang; Wu-Chen Xie; Si-Ping Yang; Tao Lu; Zhi-Hao Shi
Journal:  Eur J Med Chem       Date:  2019-11-16       Impact factor: 6.514

Review 3.  Recent advances of dual FGFR inhibitors as a novel therapy for cancer.

Authors:  Qi Liang; Juelan Wang; Liyun Zhao; Jun Hou; Yonghe Hu; Jianyou Shi
Journal:  Eur J Med Chem       Date:  2021-01-23       Impact factor: 6.514

Review 4.  The future of bladder cancer therapy: Optimizing the inhibition of the fibroblast growth factor receptor.

Authors:  Rafael Morales-Barrera; Cristina Suárez; Macarena González; Claudia Valverde; Ester Serra; Joaquín Mateo; Carles Raventos; Xavier Maldonado; Juan Morote; Joan Carles
Journal:  Cancer Treat Rev       Date:  2020-03-13       Impact factor: 12.111

Review 5.  Targeting Tumor Microenvironment by Small-Molecule Inhibitors.

Authors:  Shangwei Zhong; Ji-Hak Jeong; Zhikang Chen; Zihua Chen; Jun-Li Luo
Journal:  Transl Oncol       Date:  2019-11-27       Impact factor: 4.243
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.